The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer

Karl Pummer; Haro Stettner; Herbert Augustin; Richard Zigeuner; Helga Habermann; Luigi Schips; Ildiko Riedler; Harald Trummer; Kathrin Lipsky; Stephen B. Williams

doi:10.1159/000106096

The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer

Karl Pummer, Haro Stettner, Herbert Augustin, Richard Zigeuner, Helga Habermann, Luigi Schips, Ildiko Riedler, Harald Trummer, Kathrin Lipsky, Stephen B. Williams

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background: To investigate whether body mass index (BMI) is an independent risk factor for nonorgan-confined disease in patients with clinically localized prostate cancer. Patients and Methods: Overall, 735 patients undergoing radical prostatectomy formed the study cohort. Pathological and clinical factors with special emphasis to BMI were used to determine a model for the prediction of nonorgan-confined disease. Results: 359 patients had pathologically nonorgan-confined prostate cancer. These patients showed a significantly higher BMI than those with organ-confined disease (26.7 vs. 26.2; p = 0.0012). In multivariate analysis, age (p = 0.049), prostate-specific antigen (PSA) (p < 0.001), clinical stage (p < 0.001), prostatectomy grade (p < 0.001), and BMI (p = 0.004) were independent risk factors for nonorgan-confined disease. In patients with a serum PSA between 10.1 and 20 ng/ml only prostatectomy grade (p < 0.001) and BMI (p = 0.005) remained independent predictors. Conclusion: Patients with nonorgan-confined disease showed a significantly higher BMI than those with organ-confined stages. Moreover, BMI was an independent predictor for nonorganconfined prostate cancer. This knowledge might be helpful in patient counseling to choose between various options for the treatment of clinically localized prostate cancer.

Original language	English (US)
Pages (from-to)	489-494
Number of pages	6
Journal	Onkologie
Volume	30
Issue number	10
DOIs	https://doi.org/10.1159/000106096
State	Published - Oct 2007
Externally published	Yes

Keywords

Body mass index
Prostate cancer
Prostatectomy, radical
Staging

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1159/000106096

Cite this

@article{3e7a55e468c64fd29067145399dd3d7a,

title = "The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer",

abstract = "Background: To investigate whether body mass index (BMI) is an independent risk factor for nonorgan-confined disease in patients with clinically localized prostate cancer. Patients and Methods: Overall, 735 patients undergoing radical prostatectomy formed the study cohort. Pathological and clinical factors with special emphasis to BMI were used to determine a model for the prediction of nonorgan-confined disease. Results: 359 patients had pathologically nonorgan-confined prostate cancer. These patients showed a significantly higher BMI than those with organ-confined disease (26.7 vs. 26.2; p = 0.0012). In multivariate analysis, age (p = 0.049), prostate-specific antigen (PSA) (p < 0.001), clinical stage (p < 0.001), prostatectomy grade (p < 0.001), and BMI (p = 0.004) were independent risk factors for nonorgan-confined disease. In patients with a serum PSA between 10.1 and 20 ng/ml only prostatectomy grade (p < 0.001) and BMI (p = 0.005) remained independent predictors. Conclusion: Patients with nonorgan-confined disease showed a significantly higher BMI than those with organ-confined stages. Moreover, BMI was an independent predictor for nonorganconfined prostate cancer. This knowledge might be helpful in patient counseling to choose between various options for the treatment of clinically localized prostate cancer.",

keywords = "Body mass index, Prostate cancer, Prostatectomy, radical, Staging",

author = "Karl Pummer and Haro Stettner and Herbert Augustin and Richard Zigeuner and Helga Habermann and Luigi Schips and Ildiko Riedler and Harald Trummer and Kathrin Lipsky and Williams, {Stephen B.}",

year = "2007",

month = oct,

doi = "10.1159/000106096",

language = "English (US)",

volume = "30",

pages = "489--494",

journal = "Onkologie",

issn = "0378-584X",

publisher = "S. Karger AG",

number = "10",

}

TY - JOUR

T1 - The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer

AU - Pummer, Karl

AU - Stettner, Haro

AU - Augustin, Herbert

AU - Zigeuner, Richard

AU - Habermann, Helga

AU - Schips, Luigi

AU - Riedler, Ildiko

AU - Trummer, Harald

AU - Lipsky, Kathrin

AU - Williams, Stephen B.

PY - 2007/10

Y1 - 2007/10

N2 - Background: To investigate whether body mass index (BMI) is an independent risk factor for nonorgan-confined disease in patients with clinically localized prostate cancer. Patients and Methods: Overall, 735 patients undergoing radical prostatectomy formed the study cohort. Pathological and clinical factors with special emphasis to BMI were used to determine a model for the prediction of nonorgan-confined disease. Results: 359 patients had pathologically nonorgan-confined prostate cancer. These patients showed a significantly higher BMI than those with organ-confined disease (26.7 vs. 26.2; p = 0.0012). In multivariate analysis, age (p = 0.049), prostate-specific antigen (PSA) (p < 0.001), clinical stage (p < 0.001), prostatectomy grade (p < 0.001), and BMI (p = 0.004) were independent risk factors for nonorgan-confined disease. In patients with a serum PSA between 10.1 and 20 ng/ml only prostatectomy grade (p < 0.001) and BMI (p = 0.005) remained independent predictors. Conclusion: Patients with nonorgan-confined disease showed a significantly higher BMI than those with organ-confined stages. Moreover, BMI was an independent predictor for nonorganconfined prostate cancer. This knowledge might be helpful in patient counseling to choose between various options for the treatment of clinically localized prostate cancer.

AB - Background: To investigate whether body mass index (BMI) is an independent risk factor for nonorgan-confined disease in patients with clinically localized prostate cancer. Patients and Methods: Overall, 735 patients undergoing radical prostatectomy formed the study cohort. Pathological and clinical factors with special emphasis to BMI were used to determine a model for the prediction of nonorgan-confined disease. Results: 359 patients had pathologically nonorgan-confined prostate cancer. These patients showed a significantly higher BMI than those with organ-confined disease (26.7 vs. 26.2; p = 0.0012). In multivariate analysis, age (p = 0.049), prostate-specific antigen (PSA) (p < 0.001), clinical stage (p < 0.001), prostatectomy grade (p < 0.001), and BMI (p = 0.004) were independent risk factors for nonorgan-confined disease. In patients with a serum PSA between 10.1 and 20 ng/ml only prostatectomy grade (p < 0.001) and BMI (p = 0.005) remained independent predictors. Conclusion: Patients with nonorgan-confined disease showed a significantly higher BMI than those with organ-confined stages. Moreover, BMI was an independent predictor for nonorganconfined prostate cancer. This knowledge might be helpful in patient counseling to choose between various options for the treatment of clinically localized prostate cancer.

KW - Body mass index

KW - Prostate cancer

KW - Prostatectomy, radical

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=34648825499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648825499&partnerID=8YFLogxK

U2 - 10.1159/000106096

DO - 10.1159/000106096

M3 - Article

C2 - 17890887

AN - SCOPUS:34648825499

SN - 0378-584X

VL - 30

SP - 489

EP - 494

JO - Onkologie

JF - Onkologie

IS - 10

ER -

The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this